$8.01
1.96% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Theravance Biopharma Inc Stock price

$8.01
+0.18 2.30% 1M
-0.73 8.35% 6M
-3.23 28.74% YTD
-1.54 16.13% 1Y
-0.46 5.43% 3Y
-13.53 62.81% 5Y
-20.74 72.14% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.16 1.96%
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Key metrics

Market capitalization $391.87m
Enterprise Value $342.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.52
P/S ratio (TTM) P/S ratio 6.32
P/B ratio (TTM) P/B ratio 2.02
Revenue growth (TTM) Revenue growth 20.97%
Revenue (TTM) Revenue $62.02m
EBIT (operating result TTM) EBIT $-38.96m
Free Cash Flow (TTM) Free Cash Flow $-9.60m
Cash position $96.08m
EPS (TTM) EPS $-0.92
P/E forward negative
P/S forward 6.43
EV/Sales forward 5.62
Short interest 22.22%
Show more

Is Theravance Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Theravance Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Theravance Biopharma Inc forecast:

2x Buy
40%
3x Hold
60%

Analyst Opinions

5 Analysts have issued a Theravance Biopharma Inc forecast:

Buy
40%
Hold
60%

Financial data from Theravance Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
62 62
21% 21%
100%
- Direct Costs 6.15 6.15
5% 5%
10%
56 56
23% 23%
90%
- Selling and Administrative Expenses 55 55
11% 11%
88%
- Research and Development Expense 34 34
28% 28%
55%
-33 -33
48% 48%
-53%
- Depreciation and Amortization 6.15 6.15
5% 5%
10%
EBIT (Operating Income) EBIT -39 -39
44% 44%
-63%
Net Profit -46 -46
83% 83%
-74%

In millions USD.

Don't miss a Thing! We will send you all news about Theravance Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Theravance Biopharma Inc Stock News

Neutral
PRNewsWire
12 days ago
DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST) and will be hosting in-person meetings with the investment community at the conference.
Neutral
Seeking Alpha
about one month ago
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainright David Risinger - Leerink Partners Ernie Rodriguez - TD Cowen Liisa...
Neutral
PRNewsWire
about one month ago
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 1 Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approved Now expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months ...
More Theravance Biopharma Inc News

Company Profile

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Head office Cayman Islands
CEO Rick Winningham
Employees 99
Founded 2013
Website www.theravance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today